Nippon Protein Co., Ltd.	Established Date	Apr. 2, 2012	Spec. No.	URA-10055N-1	Page	1/4
Product Specification	Effective Date	Mar. 12, 2021				

N-Acetyl-L-Cysteine(EX) *1

N-Ac-L-Cys(EX)

: For Manufacturing, Processing or Repacking

C₅H₉NO₃S:163.19

N-Acetyl-L-Cysteine(EX), when dried, contains not less than 98.5 percent and not more than 101.0 percent of N-Acetyl-L-Cysteine (C₅H₉NO₃S).

Description: White crystals or crystalline powder; strongly acid taste. Freely soluble in water,

soluble in ethanol (96).

Identification: Compare the infrared absorption spectrum <NP TEST 35> of the sample with that of

the standard by potassium bromide disc method.

Specifications:

Item	Limit		Test Method
Specific rotation [α] $^{20}\mathrm{D}$	+21.3 to +27.0°	NP TEST 1	[dried sample, C=5,
			phosphate buffer solution*2]*3
State of solution	clear and colorless	NP TEST 2	[0.5g in 10mL of H ₂ O,
(Transmittance)	not less than 98.0%		spectrophotometer, 430nm,
			10mm cell thickness]
Heavy metals(Pb)	not more than 10ppm	NP TEST 7	[1.0g, (3), ref: 1.0mL of
			Pb Std. (0.01mg/mL)]
Zinc(Zn)	not more than 10.0ppm	EP	
Related substances	not more than 0.2%of	EP*4	
	L-cysteine		
	not more than 0.3% of		
	N, N'-diacetyl-		
	L-cystine		
	not more than 0.15% of		
	N, S-diacetyl-		
	L-cysteine		
	not more than 0.10% of		
	other impurity (each)		
	not more than 0.5% of		
	total impurities		
Loss on drying	not more than 1.00%	NP TEST 11	[1g, in vacuum, at 70°C for
			4 hours]

Nippon Protein Co., Ltd.	Established Date	Apr. 2, 2012	Spec.	URA-10055N-1	Daga	9.74
Product Specification	Effective Date	Mar. 12, 2021	No.	UKA-10033N-1	Page	2/4

Item Limit		Test Method		
Residue on ignition	not more than 0.20%	NP TEST 13 [1g, at 550°C to 650°C		
(sulfated)		for 3 hours]		
Assay	98.5 to 101.0%	EP		
pН	2.0 to 2.8	NP TEST 33 [1.0g in 100mL of H ₂ O]		

Endotoxin	less than 24.0EU/g	NP TEST 34 [C = 0.25 , kinetic-turbidimetric
		technique]

* 1 : USP, EP

* 2 : In a 50mL volumetric flask mix 2.5g of the test sample, accurately weighed, with 2mL of disodium dihydrogen ethylenediaminetetraacetate solution (1→100), add 15mL of sodium hydroxide solution (1→25), and mix to dissolve. Dilute to volume with pH 7.0 buffer prepared by mixing 29.5mL of 1mol/L sodium hydroxide, 50mL of 1mol/L potassium dihydrogen phosphate, and sufficient water to make 100mL.

* 3 : Temperature coefficient of [α] t D : -0.06°

* 4 : 1) Analytical condition

Detector: UV detector (220nm) Column: ODS (4.0mm Ø×0.25m)

Temperature: Constant temperature around 25°C

Mobile phase: Acetonitrile, water previously adjusted to pH3.0 with phosphoric

acid (3:97 V/V)

Flow rate: 1.0mL/min Injection volume: 20µL

Analytical time: Three times over the retention time for acetylcysteine

- 2) Solution preparation
 - i) Test solution

Take 800mg of sample and add 0.01mol/L hydrochloric acid solution to make 100mL.

ii) Reference solution(a)

Dilute 5.0mL of the test solution to 50.0mL with 0.01mol/L hydrochloric acid solution. Dilute 1.0mL of this solution to 100.0mL with 0.01mol/L hydrochloric acid solution.

iii) Reference solution (b)

Dissolve 80mg of L-cystine in 2mL of 1mol/L hydrochloric acid solution and dilute to 200mL with water.

Nippon Protein Co., Ltd.	Established Date	Apr. 2, 2012	Spec.	LID A 10055N 1	Daga	9 //
Product Specification	Effective Date	Mar. 12, 2021	No.	URA-10055N-1	Page	o/ 4

iv) Reference solution (c)

Dissolve 100mg of L-cysteine in 100mL of 0.01mol/L hydrochloric acid solution (L-cysteine dilute solution).

Dissolve 5mg of N,N'-diacetyl-L-cystine and 2.5mg of N,S-diacetyl-L-cysteine in 0.01mol/L hydrochloric acid solution, mix with 3mL of L-cysteine dilute solution and 4mL of Reference solution (b) and dilute to 20mL with 0.01mol/L hydrochloric acid solution. Dilute 5mL of this solution to 50 mL with the test solution.

v) Reference solution (d)

Dissolve 4mg of sodium 2-methyl-2-thiazoline-4-carboxylate in 0.01mol/L hydrochloric acid solution and dilute to 100mL with 0.01mol/L hydrochloric acid solution.

3) Calculation

Impurity contents (percentage) are calculated according to following equations.

- i) In case of L-cysteine, N, N^2 diacetyl-L-cysteine, N, S-diacetyl-L-cysteine Each impurity (%) = $(A1/A2) \times (m2/m1) \times 100 \times correction$ factor
- ii) In case of unspecified impurities

Each impurity (%) =
$$(A3 / A2) \times (m2 / m1) \times 100$$

Where,

A₁: peak area of individual impurity (L-cysteine, *N*, *N*² diacetyl-L-cystine and *N*, *S*-diacetyl-L-cysteine) in the chromatogram obtained with test solution.

A₂: peak area of acetylcysteine in the chromatogram obtained with reference solution (a).

A₃: peak area of unspecified impurity in the chromatogram obtained with test solution.

m₁: mass of the acetylcysteine in test solution (mg/mL)

m₂: mass of acetylcysteine in reference solution (a) (mg/mL)

correction factor: L-cysteine = 3.4

N,N'-diacetyl-L-cystine = 0.7

N,S-diacetyl-L-cysteine = 0.3

Nippon Protein Co., Ltd. Product Specification	Established Date	Apr. 2, 2012	Spec. No.	URA-10055N-1	Page	4/4
	Effective Date	Mar. 12, 2021				

(Remark)

Following peaks are neglected;

- i) Any peak originated from solvent used for mobile phase.
- ii) Peak due to 2-methyl-2-thiazoline-4-carboxilic acid, which is formed due to degralation of acetylcysteine in acidic solution.

End of document